Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
作者
Bruce Strober,Akihiko Asahina,Ulrich Mrowietz,Mark Lebwohl,Peter Foley,Richard G. Langley,Jonathan Barker,Christopher L. Cioffi,Nancy Cross,Maggie Haitian Wang,C. Paul
出处
期刊:Skin [National Society for Cutaneous Medicine] 日期:2021-11-05卷期号:5 (6): s52-s52被引量:1